1、该刊只有国际刊号。

2、投稿方式：在线投稿。

3、官网网址（微信公众号信息）：

https://www.sciencedirect.com/journal/eye-discovery

4、投稿系统：

https://www.editorialmanager.com/edisc/default2.aspx

5、官网邮箱：eyediscovery@fudan.edu.cn

6、出刊日期：官方暂未公布刊期信息。

7、官方微信公众号：Eye Discovery

8、微信公众号信息：2026-2028年，免收稿件处理费

2025年12月22日星期一

Call for Paper | Eye Discovery

【官方微信公众号信息】

Eye Discovery 2025年11月29日

《Eye Discovery》诚邀全球眼科科学家与临床工作者，加入这一高水平国际学术平台。提交您的最新研究成果，与世界各地同行共探眼科领域前沿！

Eye

Discovery invites global ophthalmic scientists and clinicians to join

its high-level international academic platform. Submit your latest

findings to explore ophthalmic frontiers with peers worldwide!

关于我们

Aim & Scope

《Eye Discovery》是由复旦大学附属眼耳鼻喉科医院联合顶尖学术力量创办的开放获取、同行评审国际学术期刊。期刊致力于搭建高端平台，汇聚全球眼科医师、研究人员及学者，聚焦眼科学及交叉学科的创新成果，促进学术传播与交流。随着眼科新技术飞速发展并深刻影响临床实践，亟需专属学术载体整合突破性研究、推动学科创新，这也是《Eye Discovery》的核心使命。

Eye

Discovery is an open-access, peer-reviewed international academic

journal initiated by the Eye & ENT Hospital of Fudan University in

collaboration with top academic forces. It is dedicated to creating a

high-end platform for ophthalmologists, scientists, and scholars

worldwide to focus on innovative achievements in ophthalmology and

interdisciplinary fields, and to promote academic dissemination and

exchange. With the rapid advancement of new ophthalmic technologies and

their profound impact on clinical practice, there is an urgent need for a

dedicated academic venue to integrate groundbreaking research and

propel disciplinary innovation, which constitutes the core mission of

Eye Discovery.

文章类型

Article Types

社论（Editorials）

原创研究（Original Articles）

综述（Reviews）

评论（Comments）

病例报告（Case Reports）

致编辑的信（Letters to the Editor）

潜在主题

Potential Topics

期刊欢迎涵盖眼科及相关交叉学科所有领域的原创研究与学术成果，包括但不限于：

各类眼科疾病的发病机制、诊断与治疗

眼科人工智能与数字诊断

眼科生物治疗（基因治疗、细胞治疗等）

纳米生物医学在眼科的应用

眼科相关交叉学科研究

Eye

Discovery welcomes original research and academic achievements covering

all areas of ophthalmology and related interdisciplinary disciplines,

including but not limited to:Pathogenesis, Diagnosis and Treatment of

Ophthalmic Diseases

Artificial Intelligence and Digital Diagnostics in Ophthalmology

Ophthalmic Biotherapies ( including Gene Therapy, Cell Therapy, etc.)

Nanobiomedicine Applications in Ophthalmology

Other Interdisciplinary Research in Ophthalmology

投稿及联系方式

Submission

期刊网址：https://www.scie ncedirect.com/journal/eye-discovery

Submit Your Manuscript：

https://www.editorialmanager.com/edisc/Default.aspx

Contact Email: eyediscovery@fudan.edu.cn

From 2026 to 2028, the article processing charge ( APC ) will be waived.

For

submission-related questions, please contact the editorial office via

the above email, and we will provide professional answers promptly.

Guide for authors

【官网信息】

About the journal

Aims and scope

Eye

Discovery is an open access, peer-reviewed journal for ophthalmologists

and scientists. It welcomes original articles, reviews, case reports,

editorials, commentaries, perspectives, letters and short reports

encompassing all aspects of ophthalmology/eye and its interdisciplinary

disciplines. The swift advancement of new technology and its profound

impact on ophthalmology necessitate a dedicated platform for the

dissemination and exchange of scientific research outcomes.

Article types

Eye Discovery publishes:

Editorials

should focus on significant advances, controversial issues, or

influential clinical/research trends in ophthalmology, emphasizing

insightful perspectives and critical analyses while avoiding extensive

literature reviews. These concise commentaries have a maximum length of

800 words (excluding references) and should include complete author

details (full names, affiliations, email addresses), a Conflict of

Interest (COI) statement, and an Author Contributions statement.

Research

articles report original, cutting-edge studies in ophthalmology,

including experimental investigations, clinical observations, randomized

controlled trials (RCTs). The submissions have a maximum 7,000 words

(excluding title, references, tables, and figures) and requires a

structured abstract of 300 - 500 words with Objective, Methods, Results,

Conclusion sections, avoiding abbreviations and references. Authors

should provide 3 - 8 keywords. Manuscripts should be submitted as a

single text file containing the Title Page, Main text, Acknowledgements /

Disclosure Statement, References, and Figure Legends. For randomized

controlled trials, a completed CONSORT Worksheet must be submitted.

Reviews

Article provide comprehensive synthesis of current evidence on

significant ophthalmic topics (3,000 - 5,000 words including abstract,

references, and figures/tables), which should offer original insights.

All submissions require a 250-word abstract and should include

high-quality figures/table where appropriate, with emphasis placed on

recent references (preferably published within the last five years).

Systematic reviews should additionally comply with PRISMA guidelines and

PROSPERO registration number. Each submission must include complete

author details (full names, affiliations, email addresses), a COI

statement, and an Author Contributions statement.

Comments

should provide evidence-based, constructive critique or scholarly

debate concerning specific articles recently published in this journal,

with a maximum 1,200 words including references). All submissions must

bear the title ‘Comment on [Full Original Article Title]’ and include:

(1) complete author details (full names, affiliations, email addresses);

(2) a COI statement explicitly disclosing any relationships with

authors of the original article; (3) an Author Contributions statement

specifying individual inputs.

Case Reports document clinically significant individual cases or small case series (typically ≤5

cases) that demonstrate exceptional rarity, novel ophthalmic findings,

or substantial educational value (maximum 1,200 words including main

text, references, and figure legends). Submissions should include: (1)

complete author details (full names, affiliations, email addresses); (2)

a comprehensive manuscript with detailed case description and scholarly

discussion; (3) high-quality diagnostic images with detailed legends;

(4) COI statement and Author Contributions statement; and (5)

documentation of patients consent and ethics committee approval (where

applicable), which should be declared at submission and verified before

publication.

Letters

to the Editor offer concise commentary (maximum 500 words, excluding

abstract, figures, tables, and references) that stimulates scholarly

discussion concerning recent publications in this Journal or other

significant ophthalmological research. All submissions should include a

disclosure statement.

Peer review

This

journal follows a review process. Your submission will initially be

assessed by our editors to determine suitability for publication in this

journal. If your submission is deemed suitable, it will typically be

sent to a minimum of for an independent expert assessment of the

scientific quality. The decision as to whether your article is accepted

or rejected will be taken by our editors.

Read more about peer review.

Our editors are not involved in making decisions about papers which:

they have written themselves.

have been written by family members or colleagues.

relate to products or services in which they have an interest.

Any

such submissions will be subject to the journal's usual procedures and

peer review will be handled independently of the editor involved and

their research group. Read more about editor duties.

Authors

may submit a formal appeal request to the editorial decision, provided

it meets all the requirements and follows the procedure outlined in

Elsevier’s Appeal Policy. Only one appeal per submission will be

considered and the appeal decision will be final.

Open access

We refer you to our open access information page to learn about open access options for this journal.

Ethics and policies

Ethics in publishing

Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.

Submission declaration

When authors submit an article to an Elsevier journal it is implied that:

the

work described has not been published previously except in the form of a

preprint, an abstract, a published lecture, academic thesis or

registered report. See our policy on multiple, redundant or concurrent

publication.

the article is not under consideration for publication elsewhere.

the

article's publication is approved by all authors and tacitly or

explicitly by the responsible authorities where the work was carried

out.

if

accepted, the article will not be published elsewhere in the same form,

in English or in any other language, including electronically, without

the written consent of the copyright-holder.

To verify compliance with our journal publishing policies, we may check your manuscript with our screening tools.

Authorship

All authors should have made substantial contributions to all of the following:

The conception and design of the study, or acquisition of data, or analysis and interpretation of data.

Drafting the article or revising it critically for important intellectual content.

Final approval of the version to be submitted.

Authors

should appoint a corresponding author to communicate with the journal

during the editorial process. All authors should agree to be accountable

for all aspects of the work to ensure that the questions related to the

accuracy or integrity of any part of the work are appropriately

investigated and resolved.

Changes to authorship

The

editors of this journal generally will not consider changes to

authorship once a manuscript has been submitted. It is important that

authors carefully consider the authorship list and order of authors and

provide a definitive author list at original submission.

The policy of this journal around authorship changes:

All authors must be listed in the manuscript and their details entered into the submission system.

Any

addition, deletion or rearrangement of author names in the authorship

list should only be made prior to acceptance, and only if approved by

the journal editor.

Requests

to change authorship should be made by the corresponding author, who

must provide the reason for the request to the journal editor with

written confirmation from all authors, including any authors being added

or removed, that they agree with the addition, removal or

rearrangement.

All

requests to change authorship must be submitted using this form.

Requests which do not comply with the instructions outlined in the form

will not be considered.

Only

in exceptional circumstances will the journal editor consider the

addition, deletion or rearrangement of authors post acceptance.

Publication of the manuscript may be paused while a change in authorship request is being considered.

Any

authorship change requests approved by the journal editor will result

in a corrigendum if the manuscript has already been published.

Any

unauthorized authorship changes may result in the rejection of the

article, or retraction, if the article has already been published.

......

更多详见：

https://www.sciencedirect.com/journal/eye-discovery/publish/guide-for-authors